- AU$5.34m
- AU$5.18m
- AU$0.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.98 | ||
| Price to Tang. Book | 19.98 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.16 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -259.35% | ||
| Operating Margin | -314.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.02 | 0.18 | 0.05 | 1.21 | 0.41 | n/a | n/a | 21.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InhaleRx Limited is an Australia-based healthcare company. The Company is focused on developing medicinal drug-device products to address unmet medical needs in the pain management and mental health sectors. It is engaged in the development of precision medicine delivered through inhalation. The Company is focused on the development of innovative inhaled therapeutics. The Company’s novel drug device combinations target the treatment of breakthrough cancer pain (BTcP) (IRX211) and panic disorder (PD)(IRX611a), with the objective of helping to improve the quality of life of BTcP and PD sufferers. IRX211 is a THC based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering with acute episodic bursts of breakthrough pain. It holds an approved innovation patent and has lodged an Australian provisional patent application for the treatment of BTcP with the Australian Patent Office.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 13th, 2016
- Public Since
- January 11th, 2017
- No. of Shareholders
- 568
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 213,448,224
- Address
- Level 5, 126 Phillip Street, SYDNEY, 2000
- Web
- https://inhalerx.com.au/
- Phone
- +61 383955446
- Auditors
- RSM Australia Partners
Upcoming Events for IRX
Similar to IRX
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
What is the Inhalerx share price?
As of Today at 21:19 UTC, shares in Inhalerx are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the Inhalerx share price performed this year?
Shares in Inhalerx last closed at AU$0.03 and the price had moved by -19.35% over the past 365 days. In terms of relative price strength the Inhalerx share price has underperformed the ASX All Ordinaries Index by -22.28% over the past year.
What are the analyst and broker recommendations for Inhalerx?
There is no consensus recommendation for this security.
Find out moreWhat is the Inhalerx dividend yield?
Inhalerx does not currently pay a dividend.
Does Inhalerx pay a dividend?
Inhalerx does not currently pay a dividend.
When does Inhalerx next pay dividends?
Inhalerx does not currently pay a dividend.
How do I buy Inhalerx shares?
To buy shares in Inhalerx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inhalerx?
As of the previous close price of AU$0.03, shares in Inhalerx had a market capitalisation of AU$5.34m.
Where are Inhalerx shares listed?
Here are the trading details for Inhalerx:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IRX
What kind of share is Inhalerx?
Based on an overall assessment of its quality, value and momentum Inhalerx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inhalerx share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Inhalerx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inhalerx. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -14.27%.
As of the last closing price of AU$0.03, shares in Inhalerx were trading -28.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inhalerx PE Ratio?
The Inhalerx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inhalerx?
Inhalerx's management team is headed by:
- Sean Williams - NEC
- Darryl Davies - EDR
- Elizabeth Spooner - SEC
- Nova Taylor - SEC
- Andrew Saich - NED